Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients

Study meets primary endpoint of reducing lactate levels in trauma patients treated with MP4OX

SAN DIEGO, August 31, 2010 - Sangart, Inc., today announced positive results from its Phase IIa
proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely
injured trauma patients with hemorrhagic shock causing lactic acidosis. The
study demonstrated that MP4OX, when given in addition to standard of care,
was effective at decreasing lactate levels in treated patients. During
hemorrhagic shock, inadequate perfusion of critical organs can lead to
insufficient oxygenation of tissues, which can be detected by an increase in
lactate levels. MP4OX is a novel oxygen therapeutic agent that is designed to
provide rapid oxygen delivery to ischemic tissues.

Study data show a statistically significant greater immediate and
sustained decrease of lactic acid in patients treated with MP4OX compared to
patients in the control group. The study also found that a greater proportion
of patients treated with MP4OX were able to attain normal lactate levels as
early as four hours post-treatment. Furthermore, data demonstrated a strong
trend toward outcomes benefits through multiple measures, including reducing
the average total number of days patients spent in hospital. In patients
treated with MP4OX, the median hospital stay was half that of the control
group. Serious adverse events were of equal rates and similar in nature
between the MP4OX-treated and control groups.

"Trauma patients suffer organ dysfunction from shock and lack of oxygen
supply to vital tissues. Prolonged lactic acidosis, a marker of shock,
correlates with a worse outcome and higher mortality rate. This study
suggests that MP4OX has the ability to improve oxygen delivery to the body
and subsequently reduce organ failure and other complications," said Karim
Brohi, Professor of Trauma Sciences at Barts and the London School of
Medicine & Dentistry and lead study investigator. "We are excited by the
results from this study as they suggest that MP4OX has the potential to
improve patient outcomes compared to the current standard of care in trauma."

The clinical trial was a multi-center, randomized, double-blind,
controlled study that enrolled 51 patients who suffered trauma-induced severe
hemorrhagic shock across 11 clinical sites in the United Kingdom, Germany,
France and South Africa. The primary objective of the study was to measure
reduction in lactate levels after infusion of MP4OX.

"The positive safety and efficacy data from this trial suggest that MP4OX
could be a promising new treatment option for patients suffering an acute
traumatic injury," said Brian O'Callaghan, President and Chief Executive
Officer of Sangart. "Based on these results, we plan to further development
and clinical evaluation of MP4OX and initiate Phase IIb clinical studies in
trauma patients. This study further reinforces the promise of our MP4
platform in the development of medicines designed to enhance the delivery of
oxygen to tissues and organs that are oxygen deprived."

About Trauma

Traumatic injuries, including both penetrating trauma injuries such as
bullet and knife wounds and blunt trauma from car accidents and falls, cause
the death of over 5 million people each year world-wide. Trauma is the
leading cause of death in people under the age of 44. Despite optimal care,
many patients treated for traumatic injuries suffer organ dysfunction and
failure. Elevated lactate levels (lactic acidosis), which indicate
hypoperfusion and anaerobic metabolism (oxygen deprivation) in tissues and
organs in the body, represent metabolic failure and also cardiovascular,
renal and hepatic dysfunction. Prolonged lactic acidosis correlates with
worse outcomes and higher mortality.

About MP4

Sangart's product platform is based on the MP4 molecule, an
investigational biopharmaceutical product designed to enhance the perfusion
of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in
the capillaries. Using a novel pegylation approach, Sangart produces the MP4
molecule designed at the optimal oxygen affinity, diffusion potential and
molecular size to perfuse capillaries and target oxygen delivery to tissues
specifically at risk of ischemia.

About Sangart

Sangart is a global biopharmaceutical company dedicated to developing
life-saving medicines specifically designed to enhance the perfusion and
oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen
delivery. Based on more than a decade of research, Sangart has refined the
pegylation of human hemoglobin to create a molecule, MP4, with the ability to
carry oxygen through the circulatory system to prevent and treat ischemia.

To learn more about Sangart, please visit the company's website at
www.sangart.com.

    Media Contact:
    Lauren Hamilton
    Edelman Public Relations         Office: +1-323-202-1425
    Lauren.Hamilton@edelman.com

Lauren Hamilton of Edelman Public Relations, +1-323-202-1425, Lauren.Hamilton at edelman.com, for Sangart